Norway, March 31 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today announces that it has entered a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with United Immunity Co., Ltd., based in Tokyo, Japan.Circio has previously demonstrated that its proprietary circVec circular RNA expression technology can substantially enhance and prolong the activity of conventional gene and cell therapy approaches. In this new collaboration, United Immunity will test whether circVec can be delivered with its P-LNP platform to target myeloid immune cells and extend payload expression. The aim is to determine the therapeutic potential of combining the...